- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04795778
The Validity and Reliability of FIT-HaNSA in Breast Cancer Patients
The Validity and Reliability of FIT-HaNSA (Functional Impairment Test-Hand and Neck/Shoulder/Arm) in Breast Cancer Patients
Breast cancer is the most common type of cancer among women and covers 25% of all cancers. After mastectomy and reconstruction, many patients develop various upper extremity complications such as joint movement limitation, pain, lymphedema, and axillary cord. Because of such upper extremity problems, evaluation and treatment of upper extremity functions are important. Upper extremity functions are generally evaluated with questionnaires filled out by the patients themselves and which reflect their own perspectives subjectively. However, these questionnaires cannot reflect the observations and evaluations of the clinicians. Performance tests are important for clinicians to make decisions.
With this study, we want to examine the usability of the FIT-HaNSA test in the evaluation of upper extremity functions in patients with breast cancer. Our hypothesis; The FıtHaNSA test is successful in evaluating the upper extremity function in patients with breast cancer.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Ankara, Truthahn, 06560
- Rekrutierung
- Inci Ayas
-
Kontakt:
- inci ayas
- Telefonnummer: 0 312 216 26 21
- E-Mail: inciayass@gmail.com
-
Kontakt:
- ilke keser
- Telefonnummer: 0 312 216 26 21
- E-Mail: ilkekeser@yahoo.com
-
Unterermittler:
- elif sakizli erdal
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Those whose treatments for breast cancer have been completed 18 years and over
Exclusion Criteria:
- Have a history of upper extremity surgery, excluding breast cancer surgery Have a history of upper extremity trauma Those who have orthopedic, neurological, rheumatological or cognitive impairments that may interfere with the application of the test.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Patients with breast cancer
Breast cancer patients with or without breast cancer surgery, with or without mastectomy, with or without lymphedema
|
|
Control group
Healty individuals with no disease
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
FIT-HaNSA test for upper extremity performance
Zeitfenster: For the patient group; at least 3 months after all treatments have been completed
|
FIT-HaNSA protocol includes 3 steps.In the first step of the test 3 weights of 1kg are placed on the shelf at the waist level of the individual at 10 cm intervals.The person moves these weights in rows to the 25 cm upper rack and then place them back on the lower rack.The person is asked to continue this process for 5 minutes.In the second step of the test, the first shelf is placed at eye level, the second shelf is placed 25 cm below it and the procedures in the first step are repeated.In the 3rd step, a wooden plate with 3 holes is placed perpendicular to the shelf at eye level of the individual.The hole in the middle is left empty by placing nuts and bolts in the first and third holes before.
The individual must return to the starting point in order by attaching the bolt in the first hole to the second hole, the bolt in the third hole to the first hole and finally the bolt in the second hole to the third hole and this process is 5 minutes.
|
For the patient group; at least 3 months after all treatments have been completed
|
|
Upper extremity disability
Zeitfenster: For the patient group; at least 3 months after all treatments have been completed
|
Upper extremity disability will be evaluated with DASH questionnaire (Disabilities of the Arm, Shoulder and Hand).
It is a questionnaire consisting of 30 questions that evaluates the dysfunctions of the entire upper extremity.
It consists of questions evaluating the degree of difficulty in performing different activities using the upper extremity in daily life (21 questions), pain, numbness, joint stiffness and weakness symptoms (5 questions), social life, sleep, work and psychological status (4 questions) in the last week.
|
For the patient group; at least 3 months after all treatments have been completed
|
|
Upper extremity functionality
Zeitfenster: For the patient group; at least 3 months after all treatments have been completed
|
Upper extremity functionality will be evaluated with Upper Extremity Functional Index (UEFI).
It is a questionnaire consisting of 20 questions that questions the functional difficulty of the upper extremity in daily life activities.
Each question is scored between 0 and 4 (0: extremely difficult, 4: no difficulty).
|
For the patient group; at least 3 months after all treatments have been completed
|
|
Shoulder disability
Zeitfenster: For the patient group; at least 3 months after all treatments have been completed
|
Shoulder disability will be evaluated with Shoulder Pain and Disabilty Index (SPADI).
The scale, which consists of 13 questions in total, has two subsections as pain and disability.
The pain section consists of 5 questions describing the pain of the patient, and the disability section consists of 8 questions that indicate the degree of difficulty experienced when using the upper extremity.
Each question is scored from 0 to 10 (0 is no difficulty, 10 is very difficult).
|
For the patient group; at least 3 months after all treatments have been completed
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: inci ayas, Gazi University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IAyas2
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Xijing HospitalAktiv, nicht rekrutierendBrustkrebs | Brustkrebs (Triple Negative Breast Cancer (TNBC))China
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
Shanghai Henlius BiotechNoch keine RekrutierungBrustkrebs (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi SankyoRekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
Jessica Mezzanotte SharpeRekrutierungNicht-kleinzelligem Lungenkrebs | Klassisches Hodgkin-Lymphom | Plattenepithelkarzinom Mund | Melanom (Hautkrebs) | Brustkrebs (Triple Negative Breast Cancer (TNBC)) | Invasives Mammakarzinom | Nierenzellkarzinom (Nierenkrebs) | MSI-H/dMMR RektumkarzinomVereinigte Staaten